This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
Top Analyst Reports for Johnson & Johnson, Pfizer & Target
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JNJ, PFE and TGT.
Will Earnings Reports Drive Shares This Earnings Season?
by Sejuti Banerjea
Companies that are able to leverage the pandemic to grow sales appear to have the advantage.
JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus
by Sweta Killa
Despite solid results and an upbeat view, shares of JNJ dropped as the company halted its final-phase of clinical trials for its COVID-19 vaccine candidate.
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Stock Market News for Oct 14, 2020
by Zacks Equity Research
Wall Street closed lower on Tuesday due to uncertainty on second round of coronavirus-aid package.
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
Coronavirus Cases on the Rise Again: 5 Must-Buy Stocks
by Ritujay Ghosh
Shelter-in-place stocks particularly have been taking advantage of the situation as more people are staying indoors and becoming more technology-dependent during the pandemic.
5 Must-Buy Blue Chip Stocks to Remain Safe in October
by Nalak Das
It will be prudent to invest in Dow stocks with a favorable Zacks Rank that are likely to provide solid returns in the near term.
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
by Zacks Equity Research
Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.
Dow ETF in Focus as Q3 Earnings Kick Off
by Sweta Killa
Nearly one-fourth of the blue chip firms are expected to announce results this week and in the next.
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
Johnson & Johnson (JNJ) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 10.55% and 2.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
J&J's Coronavirus Vaccine Studies Paused Post Adverse Event
by Zacks Equity Research
J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.
5 Charts to Kick-Off Earnings Season
by Tracey Ryniec
It's not just the big banks reporting earnings this week. Leaders in healthcare, transportation and manufacturing are too.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote
by Zacks Equity Research
Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Are Bank Stocks Cheap or Value Traps?
by Sheraz Mian
Driving this underperformance is the group's cyclical exposure, with the demand for credit and other banking services strongly correlated with GDP growth...
Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
Pfizer, BioNTech Begin EU Rolling Filing of Coronavirus Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech start rolling review of their coronavirus vaccine candidate, BNT162b2, in Europe.
Bull Of The Day: Jabil Inc. (JBL)
by Daniel Laboe
Jabil is one of the largest suppliers of electronic manufacturing services globally, and its shares are preparing for launch as the roaring 20s commence